|
Toll Free: (877) 796-6397 -- USA and Canada only -- |
Fax: +1-832-582-8590 Orders: +1-832-582-8158 |
Tech Support: +1-832-582-8158 Ext:3 Please provide your Order Number in the email. |
Technical Data
| Formula | C7H10NNaO7P2 |
|||
| Molecular Weight | 305.09 | CAS No. | 115436-72-1 | |
| Solubility (25°C)* | In vitro | Water | 2 mg/mL (6.55 mM) | |
| DMSO | Insoluble | |||
| Ethanol | Insoluble | |||
|
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.) |
||||
Preparing Stock Solutions
Biological Activity
| Description | Risedronate (NE 58095) sodium, a nitrogen-containing bisphosphonate, inhibits osteoclast-mediated bone resorption and modulates bone metabolism, used in the treatment of osteoporosis. |
|---|---|
| In vitro | Risedronate causes a total inhibition of colony formation whereas Etidronate has relatively little effect in calcifying fibroblastic colony-forming unit (CFU-f) cultures of rat bone marrow cells in vitro. Risedronate (1 μM) decreases the formation of colonies displaying osteoblastic characteristics such as alkaline phosphatase expression, collagen accumulation, and calcification. Risedronate (1 nM) and alendronate increases the formation of fibroblastic colonies, suggesting a mild anabolic effect, however, the formation of colonies with osteoblastic properties is not affected. [1] Risedronate significantly inhibits expression of c-Fos and nuclear factor of activated T cells (NFAT) c1 induced by RANKL in bone marrow-derived macrophages (BMMs). [2] |
| In vivo | Risedronate (1 mg/kg) significantly increases the volumetric densities of bone (Vb) and osteoblast Vob and decreases Vm more prominently in rats. [3] Risedronate causes a significant and dose-dependent reduction of tooth movement after the orthodontic force is applied in rats. [4] Risedronate prevents a reduction in periosteal bone formation and an increase in endocortical bone erosion, resulting in prevention of alterations in percent cortical bone and marrow areas. Risedronate increases osteocyte density and lacunar occupancy and prevented a GC-induced increase in cortical porosity. Risedronate and Vitamin K(2) has additive effects on osteocyte density and lacunar occupancy and a synergistic effect on cortical porosity. [5] |
Protocol (from reference)
References
Selleck's Risedronate Sodium has been cited by 2 publications
| RECOVER identifies synergistic drug combinations in vitro through sequential model optimization [ Cell Rep Methods, 2023, 3(10):100599] | PubMed: 37797618 |
| The intrasulcular application effect of bisphosphonate hydrogel toward osteoclast activity and relapse movement [ Saudi Dent J, 2021, 33(5):292-298] | PubMed: 34194193 |
RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.
SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.
NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.